SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer. We are a “start-up with a head start,” launched in 2017 with a portfolio of promising clinical therapies from Pfizer, which along with leading life science investors OrbiMed and Bain Capital, have provided strong financial backing.

Two of our programs will be entering pivotal studies in the first half of 2019: a gamma secretase inhibitor for the treatment of desmoid tumors, and a MEK 1/2 inhibitor for the treatment of neurofibromatosis type 1 patients with plexiform neurofibromas. There are currently no therapies approved for the treatment of patients diagnosed with either of these devastating tumor types. We are also advancing our MEK inhibitor as a backbone for rational combination therapies in solid tumors through partnerships with other biopharmaceutical companies.

SpringWorks has created a channel for evaluating additional assets to license from Pfizer and is also actively pursuing new licensing and partnership opportunities with other innovators. We believe in leveraging shared-value partnerships with patient advocacy groups, industry partners, academic collaborators, and investors so that together, we can unlock the full potential of science for patients.

We have assembled an experienced management team led by accomplished drug developers. Our team of SpringWorkers is focused on exceptional execution and is driven to deliver life-changing medicines for the patients who are counting on us. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients.